A comparative study of fractional carbon dioxide laser, narrowband ultraviolet B and topical tacrolimus 0.1% ointment versus narrowband ultraviolet B, topical tacrolimus 0.1% ointment in stable vitiligo
Keywords:Fractional CO2 laser, NBUVB, Tacrolimus, Vitiligo
Background: Vitiligo, an acquired pigmentary disorder of skin and mucous membrane characterized by well circumscribed depigmented macules that occur secondary to selective destruction of melanocytes. Fractional CO2 laser system is a recent advancement in the treatment of vitiligo which works on the concept of fractional photo-thermolysis, in which microscopic treatment zones are created which help in increasing the penetration of topically applied agent which indirectly improves drug efficacy.
Methods: A comparative study was conducted on 40 patients of stable vitiligo attending OPD, Dept of DVL with fractional CO2 laser, narrowband ultraviolet B (NBUVB) and topical tacrolimus 0.1% vs NBUVB, topical tacrolimus 0.1% for a duration of 4 months and patients were followed up for 12 weeks post treatment.
Results: Patients on Fractional CO2 laser in combination with NBUVB and topical tacrolimus 0.1% ointment showed >50% improvement compared with other group, with duration for initiation of pigmentation being comparatively less.
Conclusions: The treatment protocol with CO2 laser in combination with topical tacrolimus 0.1% cream and NBUVB for stable vitiligo was more effective than NBUVB and topical tacrolimus 0.1% alone and this study demonstrates that adding fractional CO2 laser improves repigmentation rate of vitiliginous lesions.
Ortonne JP. Vitiligo and other Disorders of Hypopigmentation. In: Bolognia JL, Jorizzo JL, Rapini RP (eds). Dermatology. Spain: Elsevier; 2008: 913-914.
Bleehen SS, Ebling FJ, Champion RH. Disorders of skin color. In: Champion RH, Burton JL, Ebling FJ (eds). Textbook of Dermatology. London: Blackwell Scientific Publications; 1992:1561-1622.
Moscher DB, Fitzpatrick TB, Hori Y, Ortonne JP. Disorders of pigmentation. In: Fitzpatrick TB, Is en AZ, Wolff K, Freed berg IM, Austen KF (eds). Dermatology in general medicine. New York: McGraw Hill; 1993:903.
Bolognia JL, Pawelek JM. Biology of hypopigmentation. J Am Acad Dermatol. 1988;19:217-55.
Griffiths C, Barker J, Bleiker T, Chalmers R, Creamer D. Acquired pigmentary disorders, acquired hypomelanosis. Rooks Textbook of Dermatology. 9th edition. Oxford: Wiley; 2016: 88.
Kent GA, Abadie M. Psychological effects of vitiligo: a critical incident analysis. J Am Acad Dermatol. 1996;3:895-8.
Prasad D, Pandhi R. Dogra SKanwar AJKumar B Dermatology Life Quality Index Score in vitiligo and its impact on treatment outcome. Br J Dermatol. 2003;148:373-4.
Koronne RV, Sachdevo KG. Vitiligo. Int J Dermatol. 1998;27:676-81.
Nair BKH. Vitiligo: A retrospect. Int J Dermatol. 1978;17:55-7.
Handa S, Kaur I. Vitiligo: Clinical findings in 1436 patients. J Dermatol. 1999;26:653-7.
Koranne RV, Sehgal VN, Sachdeva KG. Clinical profile of vitiligo in North India. Ind J Dermatol Venereol Leprol. 1986;52:81-2.
Howits J, Brodthagen H, Schwarts M, Thomsen K. Prevalence of vitiligo: Epidemiological survey the Isle of Bornholm, Denmark. Arch Dermatol. 1977;113:47-52.
Shajil EM, Agrawal D, Vagadia K, Marfatia YS, Begum R. Vitiligo: Clinical profiles in Vadodara, Gujarat. Indian J Dermatol. 2006;51:100-4.
Gopal K, Rama Rao GR, Kumar YH, Appa Rao MV, Vasudev PS. Vitiligo: A part of a systemic autoimmune process. Indian J Dermatol Venereol Leprol. 2007;73:162-5.
Ross EV, Yashar SS, Naseef GS, Barnette DJ, Skrobal M, Grevelink J, et al. A pilot study of in vivo immediate tissue contraction with CO2 skin laser resurfacing in a live farm pig. Dermatol Surg. 1999;25(11):851-6.
Yuan J, Chen H, Yan R, Cui S, Li YH, Wu Y, et al. Fractional CO 2 lasers contribute to the treatment of stable non-segmental vitiligo. Eur J Dermatol. 2016;26(6):592-8.
Grimes PE, Morris R, Avaniss-Aghajani E, Soriano T, Meraz M, Metzger A. Topical tacrolimus therapy for vitiligo: Therapeu.tic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol. 2004;51:52-61.
Lan CC, Yu HS, Wu CS, Kuo HY, Chai CY, Chen GS. FK506 inhibits tumour necrosis factor-alpha secretion in human keratinocytes via regulation of nuclear factor-kappaB. Br J Dermatol. 2005;153:725-32.
Moretti S, Spallanzani A, Amato L, Hautmann G, Gallerani I, Fabiani M, et al. New insights into pathogenesis of vitiligo: Imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res. 2002;15:87-92.
Lee KY, Jeon SY, Hong JW, Choi KW, Lee CY, Choi SJ, et al. Endothelin-1 enhances the proliferation of normal human melanocytes in a paradoxical manner from the TNF-a-inhibited condition, but tacrolimus promotes exclusively the cellular migration without proliferation: A proposed action mechanism for combination therapy of phototherapy and topical tacrolimus in vitiligo treatment. J Eur Acad Dermatol Venereol. 2013;27:609-1.
Nordal EJ, Guleng GE, Rönnevig JR. Treatment of vitiligo with narrowband-UVB (TL01) combined with tacrolimus ointment (0.1%) vs. placebo ointment, a randomized right/left double-blind comparative study. J Eur Acad Dermatol Venereol. 2011;25:1440.
Wu CS, Yu CL, Wu CS, Lan CC, Yu HS. Narrow-band ultraviolet-B stimulates proliferation and migration of cultured melanocytes. Exp Dermatol. 2004;13:755-63.
Wu CS, Lan CC, Yu HS. Narrow-band UVB irradiation stimulates the migration and functional development of vitiligo-IgG antibodies-treated pigment cells. J Eur Acad Dermatol Venereol. 2012;26:456-64.
Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol. 2000;42:245-53.
Parsad D, Pandhi R, Dogra S, Kumar B. Clinical study of repigmentation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiliginous patches. J Am Acad Dermatol. 2004;50:63-7.
Bhatnagar A, Kanwar AJ, Prasad D, De D. Comparison of systemic PUVA and NBUVB in treatment of vitiligo:An open prospective study. J Eur Acad Dermatol Venereol. 2007;21:638-42.